PMID: 9430359Jan 1, 1997Paper

Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial

Journal of Viral Hepatitis
N C TassopoulosS J Hadziyannis

Abstract

In spite of the availability of hepatitis B vaccine, acute hepatitis B continues to be a worldwide problem for which no specific therapy is available. We investigated the safety and the effectiveness of recombinant interferon-alpha2b (rIFN-alpha2b) in the treatment of acute hepatitis B by determining overall severity and duration of symptoms, time required to clear viral antigens and hepatitis B virus (HBV) DNA, and titre of antibodies to hepatitis B surface antigen (HBsAb), 24 weeks after the onset of therapy. One hundred patients were randomly assigned to treatment with either 3 million units (MU) (n = 34) or 10 MU (n = 33) rIFN-alpha2b or to placebo (n = 33), three times weekly for 3 weeks. Follow-up was for 24 weeks. A significantly shorter duration of the symptoms and signs of acute hepatitis was observed in patients who received 3 MU rIFN-alpha2b compared with those who received 10 MU rIFN-alpha2b or placebo. Twenty-one weeks post-therapy, patients treated with 10 MU rIFN-alpha2b showed a significantly higher geometric mean HBsAb titre than those treated with placebo (85.1 vs 35.5 IU l-1, P < 0.05). rIFN-alpha2b administration was well tolerated even in jaundiced patients. No serious side-effects were observed necessitati...Continue Reading

Citations

Apr 16, 2013·Journal of Inorganic Biochemistry·Kamila Stokowa-SołtysMałgorzata Jeżowska-Bojczuk
Jan 8, 2004·Journal of Hepatology·Patrizia Farci
Apr 5, 2003·Best Practice & Research. Clinical Gastroenterology·Patrick Marcellin, Nathalie Boyer
May 25, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hiroshi YotsuyanagiKazuhiko Koike
Jan 23, 2013·International Journal of Molecular Sciences·Tomasz Pniewski
Nov 1, 2008·International Journal of Medical Sciences·Andrea LisottiGiuseppe Mazzella
Feb 1, 2014·Clinical Journal of Gastroenterology·Makoto OketaniHirohito Tsubouchi
Jun 10, 2011·Expert Review of Gastroenterology & Hepatology·Irene N Rapti, Stephanos J Hadziyannis
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marion G Peters
Jan 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F Lok, Brian J McMahon
Mar 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jay H HoofnagleAnna S F Lok
Nov 22, 2011·Liver International : Official Journal of the International Association for the Study of the Liver·Hans L TillmannGeorge N Dalekos
Mar 31, 2016·Hepatology International·Akinobu TawadaOsamu Yokosuka
Sep 16, 2016·Clinical and Translational Gastroenterology·Ruma Rajbhandari, Raymond T Chung
Mar 22, 2005·Journal of Hepatology·Mario U MondelliAgostino Cividini
Mar 23, 2017·The Cochrane Database of Systematic Reviews·Konstantinos MantzoukisKurinchi Selvan Gurusamy
May 19, 2018·Viruses·Latavia SinghViness Pillay

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.